FDA approves Talon's Marqibo for rare leukemia
WASHINGTON (Reuters) - The Food and Drug Administration said on Thursday it has approved Talon Therapeutics Inc's Marqibo treatment for adults with a rare form of leukemia known as Philadelphia chromosome negative acute lymphoblastic leukemia.
The drug, a targeted version of generic chemotherapy drug vincristine, will be the first commercial product for Talon.
The company is majority-owned by Warburg Pincus and Deerfield Management, but shares accounting for a minority portion of its equity trade over-the-counter and were down 5 percent in afternoon trading.
Talon licensed Marqibo in 2006 after the FDA turned down an application for the drug, filed by two other companies, as a treatment for relapsed non-Hodgkin's lymphoma.
Thursday's FDA approval is for acute lymphoblastic leukemia patients who have failed at least two other therapies.
Talon's shares, which were down 5 percent at 92 cents, have more than doubled so far this year.
(Reporting by David Morgan; Editing by Gerald E. McCormick, Bernard Orr)
- U.S.'s Kerry expresses regret to India over diplomat case |
- Mega Millions winners in Georgia, California to split $648 million |
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- China confirms near miss with U.S. ship in South China Sea
- Fed cuts bond buying in first step away from historic stimulus |
During Soviet times, Sochi gained a reputation for tolerance but the city's once vibrant gay scene has been shrinking as Russia prepares to host the 2014 Winter Games. Slideshow